Elevated serum tumour necrosis factor-like weak inducer of apoptosis in alopecia areata: a possible marker of disease severity.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
accepted:
03
10
2019
pubmed:
7
10
2019
medline:
27
6
2020
entrez:
7
10
2019
Statut:
ppublish
Résumé
Alopecia areata (AA) is, an organ-specific autoimmune disease, characterized by an aberrant expression of cytokines of the T helper 1 type. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifactorial cytokine that exerts a role in the pathogenesis of inflammatory and autoimmune diseases, especially in cutaneous diseases. To estimate the serum level of TWEAK in AA and to correlate it with different parameters. This case-control study enrolled 40 patients with AA and 50 clinically healthy volunteers matched for age and sex. A blood sample (5 mL) was extracted from each participant for analysis of serum TWEAK levels by ELISA. Levels of TWEAK were significantly higher in patients with AA (mean ± SD 213.7 ± 59.2 pg/mL, range 109.1-341.6 pg/mL) than in controls (95.97 ± 13.28 pg/mL, range 80.1-152.3 pg/mL) (P < 0.001). A significant positive correlation was found between serum TWEAK level and the Severity of Alopecia Tool (SALT) score (r = 0.56, P < 0.001). To our knowledge, this study highlights for the first time a possible link between higher serum TWEAK level and AA. Serum TWEAK level appears to reflect AA disease severity.
Sections du résumé
BACKGROUND
BACKGROUND
Alopecia areata (AA) is, an organ-specific autoimmune disease, characterized by an aberrant expression of cytokines of the T helper 1 type. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifactorial cytokine that exerts a role in the pathogenesis of inflammatory and autoimmune diseases, especially in cutaneous diseases.
AIM
OBJECTIVE
To estimate the serum level of TWEAK in AA and to correlate it with different parameters.
METHODS
METHODS
This case-control study enrolled 40 patients with AA and 50 clinically healthy volunteers matched for age and sex. A blood sample (5 mL) was extracted from each participant for analysis of serum TWEAK levels by ELISA.
RESULTS
RESULTS
Levels of TWEAK were significantly higher in patients with AA (mean ± SD 213.7 ± 59.2 pg/mL, range 109.1-341.6 pg/mL) than in controls (95.97 ± 13.28 pg/mL, range 80.1-152.3 pg/mL) (P < 0.001). A significant positive correlation was found between serum TWEAK level and the Severity of Alopecia Tool (SALT) score (r = 0.56, P < 0.001).
CONCLUSION
CONCLUSIONS
To our knowledge, this study highlights for the first time a possible link between higher serum TWEAK level and AA. Serum TWEAK level appears to reflect AA disease severity.
Substances chimiques
Biomarkers
0
Cytokine TWEAK
0
TNFSF12 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
426-431Informations de copyright
© 2019 British Association of Dermatologists.
Références
Lauren C, Strazzulla L, Xiaoxue L et al. Alopecia areata. Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1-12.
Kuwano Y, Fujimoto M, Watanabe R. Serum chemokine profiles in patients with alopecia areata. Br J Dermatol 2007; 157: 466-73.
Tembre M, Sharma V. Helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol 2013; 169: 543-48.
Burkly L, Michaelson J, Hahm K et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40: 1-16.
Winkles J. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-25.
Wiley S, Winkles J. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14: 241-9.
Bilgiç Ö, Sivrikaya A, Toker A et al. Serum levels of TWEAK in patients with psoriasis vulgaris. Cytokine 2016; 77: 10-13.
Myśliwiec H, Kiluk P, Myśliwiec P et al. Influence of narrowband ultraviolet B phototherapy on serum tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in patients with psoriasis. Clin Exp Dermatol 2017; 42: 786-90.
Chen Y, Enoksson S, Johansson C et al. The expression of BAFF, APRIL and TWEAK is altered in eczema skin but not in the circulation of atopic and seborrheic eczema patients. PLoS ONE 2011; 6: e22202.
Li M, Chen T, Guo Z et al. Tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 are expressed in urticarial vasculitis. J Dermatol 2013; 40: 891-5.
Cheng H, Zhan N, Ding D et al. HPV type 16 infection switches keratinocytes from apoptotic to proliferative fate under TWEAK/Fn14 interaction. J Invest Dermatol 2015; 135: 2427-36.
Armstrong C, Galisteo R, Brown S, Winkles J. TWEAK activation of the non canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion. Oncotarget 2016; 7: 81474-92.
Zimmermann M, Koreck A, Meyer N et al. TNF like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 2011; 127: 200-7.
Olsen E, Hordinsky M, Price V et al. Alopecia areata investigational assessment guidelines. Part II. J Am Acad Dermatol 2004; 51: 440-7.
Olsen E. Investigative guidelines for alopecia areata. Dermatol Ther 2011; 24: 3111-19.
Wang-Dong X, Zhao Y, Liu Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res 2016; 64: 44-50.
Winkles J. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-25.
Burkly L, Michaelson J, Zheng T. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011; 244: 99-114.
Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004; 9: 2273-84.
Madrigal-Matute J, Fernandez-Laso V et al. TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res 2015; 108: 139-47.
Stock A, Wen J, Putterman C. Neuropsychiatric lupus, the blood brain barrier, and the TWEAK/Fn14 pathway. Front Immunol 2013; 4: 484.
Finner A. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol Ther 2011; 24: 348-54.
Liu Y, Xu M, Min X et al. TWEAK/Fn14 activation participates in Ro52-mediated photosensitization in cutaneous lupus erythematosus. Front Immunol 2017; 8: 651.
Gilhar A, Kalish R. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 2006; 5: 64-9.
Jin L, Nakao A, Nakayama M et al. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004; 122: 1175-9.
Cingi Yirün M, Yirün O, Ünal K et al. Serum TNF-related weak inducer of apoptosis (TWEAK) and TNF-related apoptosis-inducing ligand (TRAIL) levels of patients with bipolar disorder in manic episode, in remission and healthy controls. Psychiatry Res 2017; 257: 338-45.
Doerner JL, Wen J, Xia Y et al. TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. J Invest Dermatol 2015; 135: 1986-95.
Yanaba K, Yoshizaki A, Muroi E et al. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol 2009; 36: 1657-62.
Park M, Chung S, Park Y, Lee S. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 2008; 37: 173-8.